0002007997-24-000006.txt : 20240412
0002007997-24-000006.hdr.sgml : 20240412
20240412180126
ACCESSION NUMBER: 0002007997-24-000006
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240402
FILED AS OF DATE: 20240412
DATE AS OF CHANGE: 20240412
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ramaswamy Vivek
CENTRAL INDEX KEY: 0001635075
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40782
FILM NUMBER: 24842613
MAIL ADDRESS:
STREET 1: C/O ONCORE BIOPHARMA, INC.
STREET 2: 3805 OLD EASTON ROAD
CITY: DOYLESTOWN
STATE: PA
ZIP: 18902
FORMER NAME:
FORMER CONFORMED NAME: Ramasawamy Vivek
DATE OF NAME CHANGE: 20150226
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Roivant Sciences Ltd.
CENTRAL INDEX KEY: 0001635088
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 981173944
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE, 2 CHURCH STREET
CITY: HAMILTON HM11
STATE: D0
ZIP: HM11
BUSINESS PHONE: 441-295-5950
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
3
1
primary_doc.xml
PRIMARY DOCUMENT
X0206
3
2024-04-02
0
0001635088
Roivant Sciences Ltd.
ROIV
0001635075
Ramaswamy Vivek
P.O. BOX 20860
COLUMBUS
OH
43220
0
0
1
0
Common Shares
53431426
D
Stock Option (Right to Buy)
12.68
2026-03-31
Common Shares
21856138
D
Stock Option (Right to Buy)
13.78
2026-03-31
Common Shares
1753905
D
Stock Option (Right to Buy)
15.85
2026-03-31
Common Shares
5915052
D
Capped Value Appreciation Rights
11.5
2026-03-31
Common Shares
11570769
D
Reflects an award of stock options to purchase Common Shares that is fully vested.
Reflects a fully service-vested award of capped value appreciation rights ("CVARs") that, upon achievement of the hurdle price condition based on the hurdle price reflected in column 4 of Table II above on an applicable measurement date, entitle the reporting person to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price reflected in column 4 of Table II above (such excess, the "CVAR Amount"). The CVARs will be settled in a number of Common Shares determined by dividing (i) the applicable CVAR Amount by (ii) the fair market value of a Common Share as of the applicable payment date.
The reporting person became a 10% shareholder of the Issuer following the repurchase of Common Shares announced by the Issuer on April 2, 2024 and not through any transaction by the reporting person.
By: /s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy
2024-04-12
EX-24
2
vrpa_sr.txt
POWEROFATTORNEY
GRANT OF LIMITED POWER OF ATTORNEY
I, Vivek Ramaswamy, of Columbus, Ohio, do hereby make, constitute,
and appoint Stephen Roberts, of Alexandria, Virginia, my true and
lawful attorney-in-fact for me and in my name, place, and stead,
and on my behalf, and for my use and benefit authorizing him:
1 To execute in my name any documents required for the receipt,
vesting, or purchase of shares of any equity instruments (to
include common shares, stock options, warrants, grants, and
capped value appreciation rights), and any documents required
for the reporting or acknowledgment of the same; and
2 To execute in my name any documents required to complete
sell-to-cover transactions associated with the transactions
described in Paragraph 1 of this Grant.
This Grant shall continue in effect until I revoke it by separate
written instrument.
/s/ Vivek Ramaswamy
Signature
8/21/2023
Date